Advertisement
YOU ARE HERE: LAT HomeCollectionsSyntex Corp
IN THE NEWS

Syntex Corp

FEATURED ARTICLES
ARTICLES BY DATE
BUSINESS
April 28, 1995 | Times Staff And Wire Reports
Syntex to Cut Staff: The company, acquired last year by Roche Pharmaceuticals of Switzerland, has announced plans to reduce its Palo Alto work force by about 800. In its announcement, Syntex Corp. said laid-off employees will receive severance pay and benefits based on length of service. All of the layoffs are expected by year's end. Syntex, which will change its name to Roche Bioscience this summer, will be left with about 1,000 employees, a spokeswoman said.
Advertisement
BUSINESS
August 30, 1994 | From Times Staff and Wire Reports
Roche to Sell Syntex's Medical Diagnostic Unit: The company said it will sell the business under an agreement with the Federal Trade Commission, clearing the way for a $5.3-billion merger of the two companies. Roche Holding Ltd.'s $24-a-share tender offer for Syntex Corp. has been extended several times since being announced May 2 and will now expire Wednesday. Syntex's Syva Co. is a major provider of tests that detect illegal drugs.
BUSINESS
June 17, 1994 | DAVID R. OLMOS, TIMES STAFF WRITER
The first new non-prescription pain-relief remedy in a decade has landed on retailers' shelves, igniting a marketing war in the fiercely competitive $2.4-billion analgesics business. Aleve's arrival--with an expected $100-million marketing budget for the next year--could hasten a shakeout in the glutted pain reliever field, analysts said, as weak-selling products are dropped from retailers' shelves. "This is like D-Day," said Paul Freiman, chief executive of Syntex Corp.
BUSINESS
May 3, 1994 | DAVID R. OLMOS, TIMES STAFF WRITER
Syntex Corp., a pioneering Silicon Valley company that lately has fallen on hard times, has agreed to be acquired by Switzerland's Roche Holdings Ltd. in a $5.3-billion deal that would create the world's fourth-largest drug company. The merger, one of the largest ever between drug makers, comes as the pharmaceutical industry attempts to cope with health reform and intense pressure from government, health maintenance organizations and hospital groups to cut prices.
BUSINESS
June 17, 1994 | DAVID R. OLMOS, TIMES STAFF WRITER
The first new non-prescription pain-relief remedy in a decade has landed on retailers' shelves, igniting a marketing war in the fiercely competitive $2.4-billion analgesics business. Aleve's arrival--with an expected $100-million marketing budget for the next year--could hasten a shakeout in the glutted pain reliever field, analysts said, as weak-selling products are dropped from retailers' shelves. "This is like D-Day," said Paul Freiman, chief executive of Syntex Corp.
BUSINESS
March 20, 1986
Anthony A. Bourdakis was elected vice president-regulatory affairs of Syntex Corp., Palo Alto.
BUSINESS
July 8, 1987
The FDA's outside expert panel needs more time to study data on Syntex Corp.'s drug Cytovene, according to the FDA and Syntex. The drug is intended as a treatment for an infection called cytomegalovirus, a common cause of death in AIDS patients. The views of the FDA's outside expert panels traditionally carry great weight with agency officials when the time comes to decide whether to approve experimental drugs for marketing.
BUSINESS
May 3, 1994 | DAVID R. OLMOS, TIMES STAFF WRITER
Syntex Corp., a pioneering Silicon Valley company that lately has fallen on hard times, has agreed to be acquired by Switzerland's Roche Holdings Ltd. in a $5.3-billion deal that would create the world's fourth-largest drug company. The merger, one of the largest ever between drug makers, comes as the pharmaceutical industry attempts to cope with health reform and intense pressure from government, health maintenance organizations and hospital groups to cut prices.
BUSINESS
January 12, 1994 | DAVID R. OLMOS, TIMES STAFF WRITER
The Food and Drug Administration has approved a popular prescription arthritis drug for marketing as an over-the-counter pain reliever--a move that will cause competitive headaches for the makers of Advil, Tylenol and other pain remedies. The drug, naproxen sodium, is the first non-prescription pain reliever to win FDA approval since ibuprofen a decade ago.
BUSINESS
October 9, 1991 | From Times Staff and Wire Reports
Syntex Corp., FDA Reach Agreement: The agreement settles terms of a consent decree regarding advertising and promotional activities for an anti-inflammatory drug used to treat arthritis pain. Syntex said the Food and Drug Administration contended that the since-discontinued advertising and promotions for Naprosyn misrepresented that the drug has a disease-modifying effect, such as halting the progression of joint degeneration.
BUSINESS
February 15, 1990 | LINDA WILLIAMS, TIMES STAFF WRITER
Syntex Corp. said Wednesday that the Food and Drug Administration gave the company approval to market a new drug for the treatment of endometriosis, a painful disorder of the female reproductive tract that affects some 4 million to 6 million women of childbearing age in the United States. Synarel, the fourth drug that Syntex has introduced or received marketing approval for in the past year, will be available by prescription in about 10 days, the firm said.
Los Angeles Times Articles
|